Mutations at the CXCR4 interaction sites for AMD3100 influence anti-CXCR4 antibody binding and HIV-1 entry

FEBS Lett. 2003 Jul 10;546(2-3):300-6. doi: 10.1016/s0014-5793(03)00609-4.

Abstract

The interaction of the CXCR4 antagonist AMD3100 with its target is greatly influenced by specific aspartate residues in the receptor protein, including Asp(171) and Asp(262). We have now found that aspartate-to-asparagine substitutions at these positions differentially affect the binding of four different anti-CXCR4 monoclonal antibodies as well as the infectivity of diverse human immunodeficiency virus type 1 (HIV-1) strains and clinical isolates. Mutation of Asp(262) strongly decreased the coreceptor efficiency of CXCR4 for wild-type but not for AMD3100-resistant HIV-1 NL4.3. Thus, resistance of HIV-1 NL4.3 to AMD3100 is associated with a decreased dependence of the viral gp120 on Asp(262) of CXCR4, pointing to a different mode of interaction of wild-type versus AMD3100-resistant virus with CXCR4.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Sequence
  • Binding Sites
  • Flow Cytometry
  • HIV-1 / physiology*
  • Heterocyclic Compounds / metabolism*
  • Humans
  • Membrane Fusion
  • Molecular Sequence Data
  • Mutation*
  • Receptors, CXCR4 / antagonists & inhibitors
  • Receptors, CXCR4 / chemistry
  • Receptors, CXCR4 / genetics
  • Receptors, CXCR4 / immunology
  • Receptors, CXCR4 / metabolism*
  • Tumor Cells, Cultured

Substances

  • Heterocyclic Compounds
  • Receptors, CXCR4
  • plerixafor octahydrochloride